VRTX · News · 20261112N

Guidance / Outlook

VERTEX PHARMACEUTICALS INC / MA · 2026-11-12 · Importance 53 · Surprise 60

Vertex reportedly raised its full-year 2026 revenue guidance after strong third-quarter results. The report does not state the revised guidance or the size of the increase. It links the outlook to growth beyond Vertex’s core cystic fibrosis products.

Key facts